$33.20
0.27% yesterday
Nasdaq, Jun 12, 10:13 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$33.20
+1.07 3.33% 1M
-17.04 33.91% 6M
-13.84 29.42% YTD
-20.84 38.56% 1Y
+11.82 55.29% 5Y
+26.73 413.14% 10Y
+2.12 6.82% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.09 0.27%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $3.96b
Enterprise Value $3.68b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 191.72
P/S ratio (TTM) P/S ratio 206.29
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 411.17%
Revenue (TTM) Revenue $19.22m
EBIT (operating result TTM) EBIT $-565.64m
Free Cash Flow (TTM) Free Cash Flow $-407.57m
Cash position $938.22m
EPS (TTM) EPS $-5.19
P/E forward negative
P/S forward 180.12
EV/Sales forward 167.40
Short interest 15.84%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Cytokinetics, Incorporated forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
86%
Hold
14%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
19 19
411% 411%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 227 227
34% 34%
1,182%
- Research and Development Expense 358 358
8% 8%
1,861%
-556 -556
15% 15%
-2,894%
- Depreciation and Amortization 9.50 9.50
23% 23%
49%
EBIT (Operating Income) EBIT -566 -566
14% 14%
-2,943%
Net Profit -615 -615
16% 16%
-3,201%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
GlobeNewsWire
3 days ago
Program to Provide Donations to Non-Profit Organizations  Aligned with Corporate Values Deadline for Applications is August 4 th , 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program.
Neutral
GlobeNewsWire
15 days ago
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 9:20 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY.
Neutral
GlobeNewsWire
26 days ago
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today